glp-1-appeals">BCBS Diabetes Supplies Denied: CGM, Insulin Pump, and GLP-1 Appeals

Diabetes management requires continuous access to supplies and medications. When BlueCross BlueShield denies coverage for a continuous glucose monitor, insulin pump, or a diabetes drug like Ozempic or Jardiance, the consequences can be immediate and serious. Understanding how BCBS policies work — and how they vary — is the first step toward a successful appeal.

How BCBS Handles Diabetes Supply Coverage

BCBS is a federation of 35 independent local plans. BCBS Alabama, BCBS Texas, Anthem BCBS (covering multiple states), Highmark, Premera, BCBS Illinois, and other plans each publish their own medical policies for diabetes supplies. This means coverage for a continuous glucose monitor under one BCBS plan may be handled very differently from coverage under another plan in a neighboring state.

Diabetes supplies typically fall under two different benefit categories — pharmacy benefits and durable medical equipment (DME) benefits — and which pathway applies depends on your plan. CGMs, for instance, may be covered under DME (requiring a certificate of medical necessity from your physician and DME-specific authorization) or under the pharmacy benefit (processed through your plan's PBM). If you submit a CGM claim under the wrong benefit category, it will be denied on procedural grounds even if coverage exists.

Continuous Glucose Monitor (CGM) Denials

CGMs like the Dexcom G6/G7 and Abbott FreeStyle Libre 2/3 are covered by most BCBS plans, but coverage criteria vary. Common CGM denial reasons include:

• Insulin therapy requirement: Many BCBS plans historically required intensive insulin therapy (multiple daily injections or insulin pump use) as a prerequisite for CGM coverage. This criterion has been relaxed by some plans following CMS policy changes for Medicare, but not all commercial BCBS plans have followed suit.
• Type 2 diabetes on non-insulin therapy: If you have Type 2 diabetes and manage it with oral medications or GLP-1 injections rather than insulin, some BCBS plans still deny CGM coverage, arguing that real-time glucose monitoring is only medically necessary for insulin-dependent patients.
• Preferred device restriction: Your plan may have a preferred CGM brand under contract (sometimes Dexcom, sometimes Libre), and prescriptions for the non-preferred device may be denied or require a formulary exception.

If your CGM was denied, your appeal should include a physician letter explaining how real-time glucose data directly informs your treatment decisions, documentation of hypoglycemic episodes or wide glucose variability, and the clinical rationale for the specific device prescribed.

Insulin Pump Denials

Insulin pump (continuous subcutaneous insulin infusion, or CSII) coverage under BCBS plans typically requires:

• Type 1 diabetes diagnosis, or Type 2 diabetes requiring multiple daily insulin injections
• Documentation that blood glucose remains poorly controlled on multiple daily injections
• HbA1c levels above a threshold defined by the plan (commonly above 7.5–8.0%)
• Patient completion of diabetes education and demonstrated ability to use the device
• Prescribing endocrinologist letter of medical necessity

Denials often occur when the clinical documentation is incomplete — for example, when HbA1c records or injection frequency documentation are missing from the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization submission. A thorough appeal includes lab values, physician notes, and a clinical narrative explaining why the pump is medically necessary for glycemic control.

GLP-1 and SGLT2 Inhibitor Denials

GLP-1 receptor agonists (semaglutide/Ozempic, tirzepatide/Mounjaro, dulaglutide/Trulicity) and SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga) are among the most commonly denied diabetes medications under BCBS plans. These drugs sit on higher formulary tiers or require prior authorization due to their high cost.

Common denial reasons:

• Step therapy requirement: The plan may require you to first try and fail a generic metformin, sulfonylurea, or DPP-4 inhibitor before approving a GLP-1 or SGLT2 drug.
• Indication mismatch: Some BCBS plans approve GLP-1 medications only for diabetes (not for weight loss), or only for patients with cardiovascular disease risk. If the claim code doesn't match the approved indication, it gets denied.
• Non-formulary GLP-1: If a specific GLP-1 agent is not on your plan's formulary (e.g., your plan covers Trulicity but not Ozempic), you'll need a formulary exception citing clinical reasons why the formulary alternative is inadequate.

Appeals for GLP-1 and SGLT2 denials should include HbA1c lab values, documentation of prior drug trials and outcomes, any cardiovascular or renal comorbidities that make the drug medically indicated beyond glucose control, and a physician letter of medical necessity.

Finding Your Plan's Diabetes Coverage Policies

Every BCBS plan publishes medical policies for CGMs, insulin pumps, and pharmacy benefit criteria for diabetes medications. Visit your plan's website and search for "continuous glucose monitor," "insulin pump," or check your formulary for GLP-1 drugs. For Prime Therapeutics-managed plans (including BCBS Texas, Minnesota, NC, GA, and FL), check the Prime formulary at primetherapeutics.com.

Fight Back With ClaimBack

Diabetes supply denials are both clinically harmful and legally challengeable. ClaimBack helps you organize the clinical evidence, identify your plan's specific coverage criteria, and build an appeal that directly addresses the reason for denial.

Start your BCBS diabetes supply appeal now

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal